Although selective NSD1-SET inhibitors are highly relevant for aggressive NUP98-NSD1+ pediatric AML, one has to take into consideration that loss-of-function mutations of NSD1 are much more prevalent in human cancers. The gene discussed is SET; the disease is acute myeloid leukemia.